---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-052741"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:27:13.746441+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IDEAYA expects topline PFS data from darovasertib Phase 2/3 trial by late March 2026

## Summary
- 130 required PFS events confirmed by BICR; topline results from OptimUM-02 trial (1L HLA*A2-negative mUM) expected ~last week of March 2026.
- Cash, cash equivalents and marketable securities ~$1.05B as of Dec 31, 2025; expected to fund operations into 2030.
- Q4 2025 net loss $83.3M vs $130.3M in Q4 2024; R&D expenses $86.6M, down from $140.2M (prior Q4 included $75M license payment to Hengrui).
- GSK terminated Collaboration Agreement; Werner Helicase (IDE275) and Pol Theta (IDE705) programs to be transferred to IDEAYA.
- Anticipates initiation of IDE849 monotherapy registrational study in 2L+ SCLC/NEC by end of 2026.

## SEC filing metadata
- accession: 0001193125-26-052741
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312526052741/0001193125-26-052741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312526052741/idya-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-052741
- JSON: https://secwatch.observer/filing/0001193125-26-052741.json
- Plain text: https://secwatch.observer/filing/0001193125-26-052741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.